BR112013017302A2 - formulações de imunossupressor - Google Patents

formulações de imunossupressor

Info

Publication number
BR112013017302A2
BR112013017302A2 BR112013017302A BR112013017302A BR112013017302A2 BR 112013017302 A2 BR112013017302 A2 BR 112013017302A2 BR 112013017302 A BR112013017302 A BR 112013017302A BR 112013017302 A BR112013017302 A BR 112013017302A BR 112013017302 A2 BR112013017302 A2 BR 112013017302A2
Authority
BR
Brazil
Prior art keywords
api
pharmaceutically acceptable
immunosuppressant
formulations
immunosuppressant formulations
Prior art date
Application number
BR112013017302A
Other languages
English (en)
Other versions
BR112013017302B1 (pt
Inventor
Emeric Reynaud
Philippe Bouillot
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44022942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013017302(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112013017302A2 publication Critical patent/BR112013017302A2/pt
Publication of BR112013017302B1 publication Critical patent/BR112013017302B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

formulações de imunossupressor a presente invenção refere-se a uma composição farmacêutica em fase sólida compreendendo um ou mais excipientes farmaceuticamente aceitáveis e um ingrediente farmacêutico ativo (active pharmaceutical ingrediet - "api") o qual é um composto de fórmula a1 ou a2 ou um sal, solvato ou hidrato farmacologicamente aceitável do mesmo, em que o api não está exposto a um composto básico.
BR112013017302-5A 2011-01-07 2012-01-05 Composição farmacêutica em fase sólida BR112013017302B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11150431 2011-01-07
EP11150431.2 2011-01-07
PCT/EP2012/050151 WO2012093161A1 (en) 2011-01-07 2012-01-05 Immunosuppressant formulations

Publications (2)

Publication Number Publication Date
BR112013017302A2 true BR112013017302A2 (pt) 2016-10-25
BR112013017302B1 BR112013017302B1 (pt) 2021-12-07

Family

ID=44022942

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013017302-5A BR112013017302B1 (pt) 2011-01-07 2012-01-05 Composição farmacêutica em fase sólida

Country Status (35)

Country Link
US (3) US20130273161A1 (pt)
EP (2) EP2661261B1 (pt)
JP (2) JP6111202B2 (pt)
KR (2) KR102166885B1 (pt)
CN (1) CN103458877B (pt)
AR (2) AR084801A1 (pt)
AU (1) AU2012204835B2 (pt)
BR (1) BR112013017302B1 (pt)
CA (1) CA2823616C (pt)
CL (1) CL2013001979A1 (pt)
CO (1) CO6761402A2 (pt)
CY (1) CY1122182T1 (pt)
DK (1) DK2661261T3 (pt)
EA (1) EA026144B9 (pt)
EC (1) ECSP13012812A (pt)
ES (1) ES2751920T3 (pt)
GT (1) GT201300178A (pt)
HR (1) HRP20191842T1 (pt)
HU (1) HUE045612T2 (pt)
IL (1) IL227094B (pt)
JO (1) JO3619B1 (pt)
LT (1) LT2661261T (pt)
MA (1) MA34897B1 (pt)
MX (2) MX371290B (pt)
MY (1) MY161162A (pt)
PE (1) PE20140216A1 (pt)
PL (1) PL2661261T3 (pt)
PT (1) PT2661261T (pt)
SG (1) SG191286A1 (pt)
SI (1) SI2661261T1 (pt)
TN (1) TN2013000257A1 (pt)
TW (2) TWI610672B (pt)
UA (1) UA114283C2 (pt)
WO (1) WO2012093161A1 (pt)
ZA (1) ZA201304465B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201692043A1 (ru) * 2014-04-10 2017-02-28 Новартис Аг Лекарственная форма иммунодепрессанта
SG11201607894RA (en) * 2014-04-10 2016-10-28 Novartis Ag S1p modulator immediate release dosage regimen
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
HUE061697T2 (hu) 2015-07-03 2023-08-28 Astellas Pharma Inc Stabil gyógyszerkészítmény orális adagolásra
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
BR112020005703A2 (pt) 2017-09-27 2020-10-20 Novartis Ag formulação parentérica compreendendo siponimod
MX2020007268A (es) 2017-09-29 2020-08-17 Novartis Ag Regimen de dosificacion de siponimod.
CA3074416A1 (en) 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
WO2021214717A1 (en) 2020-04-23 2021-10-28 Novartis Ag Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome
WO2023172508A1 (en) * 2022-03-09 2023-09-14 Isp Investments Llc Co-processed excipient composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225964B1 (en) 1994-07-12 2008-01-28 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
KR20050055050A (ko) * 2002-11-07 2005-06-10 니폰 제톡 가부시키가이샤 구강용 조성물 기제 및 구강용 조성물
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
HUE027696T2 (en) * 2007-10-12 2016-10-28 Novartis Ag Preparations containing sphingosine-1-phosphate (S1P) receptor modulators
PL2326325T3 (pl) 2008-08-18 2015-04-30 Novartis Ag Pochodna azetydyny do leczenia neuropatii obwodowych
KR20110101159A (ko) * 2008-12-18 2011-09-15 노파르티스 아게 신규 염
BRPI0923176B8 (pt) * 2008-12-18 2021-05-25 Novartis Ag forma cristalina do sal de hemifumarato de ácido 1-(4-{1-[(e)- 4-ciclo-hexil-3-trifluormetil-benzilóxi-imino]-etil}-2- etil-benzil)-azetidina-3-carboxílico e composição farmaceutica
MX2011006610A (es) 2008-12-18 2011-06-30 Novartis Ag Nueva forma polimorfica de acido 1-(4-{l-[(e)-4-ciclohexil-3 -trifluorometil-benciloxi-imino]-etil)-2-etil-bencil)-azetidin-3 carboxilico.
BRPI0923213A2 (pt) 2008-12-22 2016-01-26 Novaris Ag regime de dosagem de um agonista do receptor para s1p.

Also Published As

Publication number Publication date
KR20190025727A (ko) 2019-03-11
CO6761402A2 (es) 2013-09-30
HUE045612T2 (hu) 2020-01-28
EP2661261A1 (en) 2013-11-13
US20130273161A1 (en) 2013-10-17
CA2823616C (en) 2019-01-29
AR084801A1 (es) 2013-06-26
PT2661261T (pt) 2019-10-25
SI2661261T1 (sl) 2019-11-29
SG191286A1 (en) 2013-07-31
KR20140037815A (ko) 2014-03-27
KR102166885B1 (ko) 2020-10-19
JP6324569B2 (ja) 2018-05-16
MX371290B (es) 2020-01-24
MX357304B (es) 2018-07-04
EA201391018A1 (ru) 2013-11-29
CL2013001979A1 (es) 2013-11-22
TW201249438A (en) 2012-12-16
IL227094B (en) 2019-03-31
NZ612420A (en) 2015-05-29
KR101951966B1 (ko) 2019-02-25
MY161162A (en) 2017-04-14
LT2661261T (lt) 2019-10-25
TWI610672B (zh) 2018-01-11
EP3590507A1 (en) 2020-01-08
US20200199069A1 (en) 2020-06-25
CY1122182T1 (el) 2020-11-25
EP2661261B1 (en) 2019-07-31
US20220064110A1 (en) 2022-03-03
EA026144B9 (ru) 2021-10-26
PE20140216A1 (es) 2014-03-01
JP2014501770A (ja) 2014-01-23
JP6111202B2 (ja) 2017-04-05
CN103458877A (zh) 2013-12-18
CN103458877B (zh) 2016-06-08
MX2013007909A (es) 2013-08-29
AR124662A2 (es) 2023-04-19
WO2012093161A1 (en) 2012-07-12
MA34897B1 (fr) 2014-02-01
AU2012204835B2 (en) 2015-07-09
ES2751920T3 (es) 2020-04-02
CA2823616A1 (en) 2012-07-12
HRP20191842T1 (hr) 2019-12-27
BR112013017302B1 (pt) 2021-12-07
AU2012204835A1 (en) 2013-08-01
EA026144B1 (ru) 2017-03-31
TW201609092A (zh) 2016-03-16
JO3619B1 (ar) 2020-08-27
PL2661261T3 (pl) 2020-01-31
ZA201304465B (en) 2014-02-26
DK2661261T3 (da) 2019-10-21
GT201300178A (es) 2014-12-30
TN2013000257A1 (en) 2014-11-10
UA114283C2 (uk) 2017-05-25
TWI583380B (zh) 2017-05-21
JP2017141248A (ja) 2017-08-17
ECSP13012812A (es) 2013-09-30

Similar Documents

Publication Publication Date Title
BR112013017302A2 (pt) formulações de imunossupressor
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
MX2015010971A (es) Derivado novedoso de pirazol.
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
WO2013188792A3 (en) Neuroactive steroids, compositions, and uses thereof
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
ECSP12012290A (es) Formulaciones farmacéuticas
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
BR112018002115A2 (pt) benzamidas aneladas
MX364400B (es) Compuestos de tetraciclina.
EA201591177A1 (ru) Трициклические соединения для ингибирования канала cftr
EA201692298A1 (ru) Производные карбоксамидов
EA201490573A1 (ru) Соединение бензотиазолона
BR112015025058A2 (pt) composição farmacêutica capaz de controlar facilmente o padrão de dissolução de lacosamida ou de um sal farmaceuticamente aceitável da mesma
BR112016009214A8 (pt) uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
TN2012000568A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
TR200802061A2 (tr) Yüksek oranda aktif madde içeren farmasötlk formülasyon.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/01/2012, OBSERVADAS AS CONDICOES LEGAIS.